Neurology: What is the relationship between AD CSF indicators and alpha-synuclein

Cerebrospinal fluid (CSF) features of neuropathological changes (ADNC) in Alzheimer's disease (ADNC) include a decrease

Figure 1: Cover art of the paper

Because of their sensitivity to the neuropathological process of AD, these CSF biomarkers can be used in life to stratify AD patients with individuals without AD, including suspected non-AD pathophysiology (SNAP

It is not yet known how the accompanying αSyn affects CSF, which is a problem with any CSF-based strategies for detecting AD, including the t-tau/Aβ42 ratio

As a result, αSyn may affect CSF biomarkers in a different way than ADNC, affecting diagnostic accuracy and interpretation

To address this, Katheryn Alexandra Quilico Cousins of the University of Pennsylvania and others compared CSF Aβ42, p-tau181, t-tau, and Ng levels of autopsy-confirmed AD and AD mixed with αSyn (AD+αSyn); We used αSyn and non-impaired control groups without ADNC as reference groups

The main goal is to test whether the AD CSF biomarker differs

They next tested a direct association

Inclusion criteria were neuropathological diagnosis of AD, mixed AD+αSyn, and αSyn

Participants had 61 AD, 39 AD+αSyn hybrids, 20 αSyn, and 61 controls

Figure 2: Graph of the paper results

The analysis of variance showed that the p-tau181 (F(1,94) = 17, p=0), t-t-tau (F(1,93) = 11, p=0.

αSyn is not a significant factor in Aβ42 (p=1

The results showed that the accompanying pathological changes in αSyn in AD patients were associated with lower CSF p-tau181, t-t-tau, and Ng levels, and could affect the diagnostic accuracy